Mammoth Biosciences Named to Fast Company’s 2022 List of the Next Big Things in Tech

November 17, 2022 |

3 min read

Mammoth Biosciences , Inc., a biotech company harnessing next-generation CRISPR technology to cure and detect disease, today announced that it has been named to Fast Company’s 2022 Next Big Things in Tech list, honoring the technology breakthroughs that promise to shape the future of their industries.

List Recognizes Tech Breakthroughs Across Industries That Promise to Transform the Future

BRISBANE, Calif.--(BUSINESS WIRE)-- Mammoth Biosciences, Inc., a biotech company harnessing next-generation CRISPR technology to cure and detect disease, today announced that it has been named to Fast Company’s 2022 Next Big Things in Tech list, honoring the technology breakthroughs that promise to shape the future of their industries. Mammoth was recognized for the transformative impact of its ultracompact CRISPR systems on human health.

This year, 83 technologies developed by established companies, startups, or research teams are highlighted for their cutting-edge advancements and potential to impact consumers, businesses, and society overall. While not all of the technological developments are available in the market yet, each one is reaching key milestones in order to have a proven impact in the next five years. Fast Company also recognized 41 honorable mentions.

Mammoth harnesses the natural diversity of life to address the challenges of legacy CRISPR enzymes to enable a broader scope of applications. Driven by its protein discovery and engineering engine, the company develops novel CRISPR systems and technologies that are equipped with unique properties. Mammoth’s proprietary systems have the potential to deliver on the promise of CRISPR to provide patients with permanent genetic cures and to power a new method of decentralizable molecular detection. For instance, Mammoth’s therapeutic efforts include pioneering the development of ultracompact Cas14- and CasΦ-based CRISPR systems that can facilitate delivery for in vivo genome editing.

“We’re delighted that the potential of our technology is being recognized,” said Trevor Martin, co-founder and Chief Executive Officer of Mammoth Biosciences. “We firmly believe that the genome editing potential of our CRISPR systems can redefine the healthcare landscape by eliminating the underlying drivers of many genetic diseases that are currently considered intractable.”

“Technology breakthroughs and cutting-edge advancements promise to be the solution to some of the world’s most pressing issues. Fast Company is excited to highlight some of the organizations, of all sizes and industry backgrounds, whose technology advancements today will lead to a better tomorrow,” says Brendan Vaughan, Editor-in-Chief of Fast Company.

Click here to see the final list.

The Winter 2022/2023 issue of Fast Company is available online now and will hit newsstands on December 6.

About Fast Company

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The Editor-in-Chief is Brendan Vaughan. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at fastcompany.com.

About Mammoth Biosciences

Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo and ex vivo therapies, and to democratize disease detection with on-demand diagnostics. By leveraging its internal research and development, and exclusive licensing to Cas12, Cas13, Cas14 and Casɸ enzymes, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences was co-founded by CRISPR pioneer and Nobel laureate Jennifer Doudna, along with Trevor Martin, Janice Chen and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX and 8VC.